Review: Tau in biofluids – relation to pathology, imaging and clinical features

Neuropathology and Applied Neurobiology

Volumn 43, Issue 3, 2017, Pages 194-199

  Zetterberg, H ^a,b,c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; plasma; tau

Indexed keywords

BIOLOGICAL MARKER; PHOSPHO TAU PROTEIN; TAU PROTEIN; TOTAL TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; BODY FLUID; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HISTOPATHOLOGY; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; TAUOPATHY; METABOLISM; PATHOLOGY;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; TAU PROTEINS;

EID: 85017326518     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12378     Document Type: Review

References (40)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245–9
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913–7
3. Nukina N, Ihara Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 1986; 99: 1541–4
4. Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M. Tau: From research to clinical development. Alzheimers Dement 2016; 12: 1033–1039
5. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012; 2: a006247
6. Saman S, Kim W, Raya M, Visnick Y, Miro S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 2012; 287: 3842–9
7. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in Amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 2013; 5: 194re192
8. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828–34
9. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231–45
10. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016; 15: 673–84
11. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001; 297: 187–90
12. Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A. Neurochemical aftermath of amateur boxing. Arch Neurol 2006; 63: 1277–80
13. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 2007; 12: 255–60
14. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004; 61: 95–102
15. Mattsson N, Savman K, Osterlundh G, Blennow K, Zetterberg H. Converging molecular pathways in human neural development and degeneration. Neurosci Res 2010; 66: 330–2
16. Grahn A, Hagberg L, Nilsson S, Blennow K, Zetterberg H, Studahl M. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol 2013; 260: 1813–21
17. Kondziella D, Zetterberg H. Hyperphosphorylation of tau protein in superficial CNS siderosis. J Neurol Sci 2008; 273: 130–2
18. Ikeda T, Noto D, Noguchi-Shinohara M, Ono K, Takahashi K, Ishida C, Yoshita M, Kawaguchi M, Kawahara N, Iwasa K, Tomita K, Yamada M. CSF tau protein is a useful marker for effective treatment of superficial siderosis of the central nervous system: two case reports. Clin Neurol Neurosurg 2010; 112: 62–4
19. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006; 129(Pt 11): 3035–41
20. Seppälä TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykkö OT, Helisalmi S, Alafuzoff I, Hiltunen M, Jääskeläinen JE, Rinne J, Soininen H, Leinonen V, Herukka SK. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012; 78: 1568–75
21. Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, Morris JC, Holtzman DM. Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2012; 26: 314–21
22. Glodzik L, Mosconi L, Tsui W, deSanti S, Zinkowski R, Pirraglia E, Rich KE, McHugh P, Li Y, Williams S, Ali F, Zetterberg H, Blennow K, Mehta P, deLeon MJ. Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol Aging 2012; 33: 1215–27
23. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 1989; 37: 209–15
24. Smith R, Wibom M, Olsson T, Hagerstrom D, Jogi J, Rabinovici GD, Hansson O. Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer's disease patient with presenilin-1 mutation. J Alzheimers Dis 2016; 51: 339–43
25. Romero I, Jorgensen P, Bolwig G, Fraser PE, Rogaeva E, Mann D, Havsager AM, Jorgensen AL. A presenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease. NeuroReport 1999; 10: 2255–60
26. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 2009; 27: 458–64
27. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010; 74: 1531–7
28. Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 2014; 71: 476–83
29. Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, Blennow K, Zetterberg H, Wilson DH. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 2013; 84: 351–6
30. Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 2013; 5: 9
31. Shahim P, Tegner Y, Wilson DH, Randall J, Skillback T, Pazooki D, Kallberg B, Blennow K, Zetterberg H. Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol 2014; 71: 684–92
32. Bogoslovsky T, Wilson D, Chen Y, Hanlon D, Gill J, Jeromin A, Song L, Moore C, Gong Y, Kenney K, Diaz-Arrastia R. Increases of plasma levels of glial fibrillary acidic protein, tau, and amyloid beta up to 90 days after traumatic brain injury. J Neurotrauma 2017; 34: 66–73
33. Olivera A, Lejbman N, Jeromin A, French LM, Kim HS, Cashion A, Mysliwiec V, Diaz-Arrastia R, Gill J. Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol 2015; 72: 1109–16
34. Arendt T, Stieler J, Holzer M. Tau and tauopathies. Brain Res Bull 2016; 126: 238–292
35. Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF. Characterization of novel CSF tau and ptau biomarkers for Alzheimer's disease. PLoS ONE 2013; 8: e76523
36. Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B, Trenkwalder C, Van Swieten J, Chiu WZ, Borroni B, Cámara A, Cheshire P, Williams DR, Lees AJ, deSilva R. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012; 123: 396–405
37. Lewczuk P, Lelental N, Lachmann I, Holzer M, Flach K, Brandner S, Engelborghs S, Teunissen CE, Zetterberg H, Molinuevo JL, Mroczko B, Blennow K, Popp J, Parnetti L, Chiasserini D, Perret-Liaudet A, Spitzer P, Maler JM, Kornhuber J. Non-phosphorylated tau as a potential biomarker of Alzheimer's disease: analytical and diagnostic characterization. J Alzheimers Dis 2017;55:159–170
38. Russell CL, Mitra V, Hansson K, Blennow K, Gobom J, Zetterberg H, Hiltunen M, Ward M, Pike I. Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates. J Alzheimers Dis 2017;55:303–313
39. Barthélemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Junot C, Becher F, Lehmann S. Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer's disease, progressive supranuclear palsy, and dementia with lewy bodies. J Alzheimers Dis 2016; 51: 1033–43
40. McAvoy T, Lassman ME, Spellman DS, Ke Z, Howell BJ, Wong O, Zhu L, Tanen M, Struyk A, Laterza OF. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin Chem 2014; 60: 683–9